Available EXPANDED_ACCESS NCT05047328

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease Grade II-IV in Adults and in Children Over 28 Days of Age

Sponsor: ElsaLys Biotech

Conditions Steroid Resistant Acute Graft Versus Host Disease

Interventions inolimomab

Updated 3 times since 2021 Last updated: Sep 16, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05047328, this observational or N/A phase trial focuses on Steroid Resistant Acute Graft Versus Host Disease and remains ongoing. Sponsored by ElsaLys Biotech, it has been updated 3 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Oct 2021 — Jul 2024 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ElsaLys Biotech

Data source: ElsaLys Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lyon, France